Clinical Trials Sponsored by Bial - Portela C S.A

Total 132 results

Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Opicapone in Clinical Practice (OPTIPARK)

Parkinson's Disease With Wearing-off Motor Fluctuations

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Bial - Portela C S.A.

Completed

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Painful Diabetic Neuropathy
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.

Hypertension and Chronic Heart Failure

Netherlands
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Parkinson
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Parkinson Disease

Canada
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Parkinson

Canada
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Epilepsy
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Parkinson's Disease
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.

Completed

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Refractory Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours

Epilepsy

Romania, Slovakia
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
Bial - Portela C S.A.

Recruiting

OpiCapone Effect on Motor Fluctuations and pAiN (OCEAN)

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Safety and Efficacy of BIA 5-1058 in PAH

Pulmonary Arterial Hypertension

Austria, Germany, Italy, Portugal, Spain, United Kingdom
Bial - Portela C S.A.

Active, not recruiting

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) (EPSILON)

Parkinson

Bulgaria
Bial - Portela C S.A.

Completed

Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH

Pulmonary Arterial Hypertension

Spain
Bial - Portela C S.A.

Completed

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of Food on BIA 5-1058

Pulmonary Arterial Hypertension
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan

Pulmonary Arterial Hypertension

Germany

3

Subscribe